Get the latest tech news
From Netanya labs to global race: Teva develops antibody targeting celiac and autoimmune diseases
Backed by up to $500 million deal, Teva advances experimental antibody for celiac and vitiligo, aiming to stop autoimmune disease at its source; researcher offers rare look inside complex path from lab to patients
None
Or read this on r/technology
